EUVIMEDEUVIMED entdecken
LeserbriefFallbericht

FH -mutant glioma displaying the epigenetic signature of IDH -mutant astrocytomas

Valentina Zschernack iD, Christian Thomas iD, Christina Schaub, Glen Kristiansen, Andreas Waha, Tobias Goschzik, Ulrich Herrlinger, Torsten Pietsch

Journal of Neuropathology & Experimental Neurology · 2024

DOI: 10.1093/jnen/nlae064 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2024. Verfasst von Valentina Zschernack und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, DGNN Brain Tumor Reference Center, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Astrocytoma, Brain Neoplasms, Epigenesis, Genetic, Glioma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: Since the 2016 WHO classification of tumors of the CNS, diffusely infiltrating astrocytic tumors with an IDH mutation were separated from IDH-wildtype diffuse astrocytic tumors and now represent the novel entity called “astrocytoma, IDH-mutant” in the latest 2021 WHO classification of CNS tumors.1 IDH mutations in astrocytic tumors were first described in 2008.2 The mutant IDH enzyme produces the oncometabolite 2-hydroxyglutarate, which modulates gene regulation via epigenetic changes.3 A characteristic feature of astrocytomas with IDH1/2 mutations is the CpG island methylator phenotype (CIMP).4 Recently, a missense mutation in the fumarate hydratase (FH) gene (p.Met195Val), which is also part of the citrate cycle, was described in an IDH1/2 wildtype glioma with CIMP and epigenetic profile of an IDH-mutant astrocytoma.5 However, more than 12 000 sequence variants were detected in that case and the significance of the FH mutation remained uncertain. Here we describe the diagnostic features and clinical course of an adult glioma with a 3 basepair in-frame deletion of FH (p.Tyr68del), further corroborating the hypothesis that FH and IDH mutations may induce gliomagenesis through similar epigenetic mechanisms. A 20-year-old, previously healthy, female patient presented with recurrent headache episodes and two generalized tonic-clonic seizures. Imaging showed a solid tumor in the left frontal region with a dimension of 5 × 5 cm and partial contrast enhancement (Figure 1A and B). After surgery, histological examination revealed a diffusely infiltrating, moderate to highly cellular glial tumor with increased proliferation (Figure 1C). Endothelial cell proliferation and areas of necrosis were absent. The tumor stained negative for mutant IDH-R132H protein and for ATRX on immunohistochemistry. DNA methylation analysis (EPIC bead array) indicated significant concordance with the methylation class “diffuse glioma, IDH mutant” (v12.5, calibrated score: 0.95). High-resolution, genome-wide copy number analysis by molecular inversion probe array depicted several chromosomal changes, partly with a mosaic pattern, including a partial loss of chromosome 1q containing the FH gene (Figure 1D). By next generation panel sequencing (NGS), a TP53 mutation (p.Arg213Ter) and a frameshift deletion of the ATRX gene, and an ERCC2 (p.Gly713Arg) single nucleotide variant were detected, whereas the IDH1/2 genes were wildtype. Whole exome sequencing (Twist Exome 2.0, Twist Bioscience) revealed a homozygous 3 basepair in-frame deletion in exon 2 of the FH gene (NM_000143.3: c.202_204del; p. Tyr68del, mutant allele frequency: 85%). Immunohistochemistry for FH showed a loss of the FH protein in tumor cells (Figure 1E). t-Distributed stochastic neighbor embedding (t-SNE) analysis together with the v11b4 cohort of the Heidelberg Classifier revealed close proximity of this case to the group of IDH-mutant astrocytomas (Figure 1F).6 (A, B) Magnetic resonance images prior to surgery, with contrast agent (A: T1 sequence; B: T2 sequence). (C, E) H&E staining (C) and FH immunohistochemistry of the tumor tissue showing increased cell density, lack of necrosis and endothelial proliferation, and reduced expression of FH in tumor cells (E). (D) High-resolution copy number profile of the tumor, highlighting a hemizygous loss of the CDKN2A gene locus, copy number losses of whole chromosomes 18, 22, and X, as well as focal losses on 1p and 1q and focal gain of 7p, and mosaic losses of chromosome 6 and a region of chromosome 2q. Chromosome 8 showed numerical gain. Not visible in this copy profile were further copy-neutral losses-of-heterozygosity of chromosomes 11q and 17. (F) t-SNE dimension reduction plot of the genome-wide DNA methylation profile of this case alongside the v11b4 reference set of CNS tumors. After the diagnosis was made, the patient received radiotherapy for 6 weeks (ad 59.4 Gy) and subsequent temozolomide (TMZ) therapy (according to CATNON protocol, dose 150-200 mg/m2 per day on day 1-5 in a 28-day cycle). After a follow-up of 12 months and 11 courses of TMZ the patient is tumor progression free. The FH gene encodes for both its mitochondrial and cytosolic enzyme variants that catalyze the reversible hydration of fumarate to L-malate.7 Dysfunctional FH leads to fumarate accumulation that impairs the citrate cycle and inhibits the succinate dehydrogenase.8 As a result, a complex metabolic reprogramming occurs. Fumarate accumulation also induces an oncogenic signaling via fumarate-dependent succination.8,9 It acts as a competitive inhibitor of the alpha-ketoglutarate-dependent dioxygenases (αKGDD), which are involved in DNA and histone demethylation and protein hydroxylation.8 For instance, ten-eleven translocation (TET) proteins catalyze DNA demethylation.10 Fumarate can affect the TET-dependent DNA demethylation by blocking it and thus disturbing gene expression.8 Impairment of FH is linked to the suppression of the CDKN2A gene, encoding the p16 protein, via hypermethylation.11 Germline FH-mutations are related to a hereditary leiomyomatosis and renal cell carcinoma syndrome.12 Comprehensive analysis of DNA methylation data disclosed a high level of a DNA hypermethylation phenotype and significant immune cell infiltration among FH-deficient RCC.13 Interestingly, germline FH mutations are also found in multiple/malignant pheochromocytoma or paraganglioma and display a similar pattern of epigenetic deregulation as the more common succinate dehydrogenase-mutated pheochromocytoma/paraganglioma.14 These findings suggest that FH mutations are involved in the pathogenesis of various types of cancer and primarily cause epigenetic changes leading to a hypermethylator phenotype. In diagnostic neuropathology, IDH1/2-wildtype astrocytic tumors with the DNA methylation profile of IDH-mutant astrocytoma should therefore be screened for other citrate cycle gene mutations, including FH. Since germline mutations in FH have been linked to a hereditary tumor syndrome, a potential screening for brain tumors in those patients should be considered.12 The specific impact of FH protein loss on the biology of glial tumors such as the index case presented here and the therapeutic implications have to be further investigated. The authors thank Marco Gessi, MD for his careful reading of this text. None declared. The authors declare that they have no competing interests. The patient gave written informed consent to this case report.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AstrocytomaBrain NeoplasmsEpigenesis, GeneticGliomaIsocitrate DehydrogenaseMutationFemaleHumansYoung Adult

Substanzen

Isocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Neuropathology, DGNN Brain Tumor Reference Center, University Hospital Bonn, Bonn, Germany.
  • Institute of Neuropathology, University Hospital Münster, Münster, Germany.
  • Department of Neurooncology, Center for Neurology and Center of Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
  • Institute of Pathology, University Hospital Bonn, Bonn, Germany.

ORCID-Profile: Valentina Zschernack, Christian Thomas

Zitieren

APA

Zschernack, V., Thomas, C., Schaub, C., Kristiansen, G., Waha, A., Goschzik, T., Herrlinger, U., & Pietsch, T. (2024). FH -mutant glioma displaying the epigenetic signature of IDH -mutant astrocytomas. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlae064

Vancouver

Zschernack V, Thomas C, Schaub C, Kristiansen G, Waha A, Goschzik T, et al. FH -mutant glioma displaying the epigenetic signature of IDH -mutant astrocytomas. Journal of Neuropathology & Experimental Neurology. 2024. doi:10.1093/jnen/nlae064

BibTeX
@article{Zschernack2024,
  author = {Zschernack, Valentina and Thomas, Christian and Schaub, Christina and Kristiansen, Glen and Waha, Andreas and Goschzik, Tobias and Herrlinger, Ulrich and Pietsch, Torsten},
  title = {FH -mutant glioma displaying the epigenetic signature of IDH -mutant astrocytomas},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2024},
  doi = {10.1093/jnen/nlae064}
}
Kostenlos starten →